CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
No net buying or selling imbalance over the last 3 months
No net buyers or sellers account for the net balance. There is no cluster of three distinct buyers within 30 days. We found no CEO/CFO purchases over 12 months.
Only open-market P purchases and S sales count toward the signal. Vesting, options, taxes and gifts remain in the source data but do not trigger alerts. Rule 10b5-1 trades are shown as informational.
3-month balance
$0.00
0 buyers · 0 sellers
12-month purchases
$0.00
0 distinct insiders
12-month sales
$0.00
0 distinct insiders
Highlighted alerts
0
0 Rule 10b5-1 trades treated as informational
Buying cluster · 30 days
Fewer than three distinct buyers
CEO/CFO purchases · 12 months
No executive purchases found
Get CELZ insider trades by API
The same filtered trades as JSON for your scripts, alerts or AI agent, for 5,500+ US companies — plus sentiment, news, financials and breakout setups. Free · every API · 1,000 requests a month · no card required.
CELZ overview: breakout setup, X sentiment and insiders in one page →
The value is in what we do not call a signal.
The SEC XML stores every transaction. Raspberry keeps that evidence, reads the footnotes and separates voluntary open-market activity from vesting, option exercises, gifts, tax withholding, stock purchase and dividend reinvestment plans and pre-programmed 10b5-1 trades.
- Code
- A
- Shares
- 1,000,000
- Price
- —
- Footnotes
- 2
The shares of common stock were issued to Creative Acquisition Corp. ("CAC") pursuant to a Stock Purchase Agreement dated September 24, 2026 (the "SPA"), between CAC and the Issuer, pursuant to which the Issuer purchased 4,000,000 shares of common stock of BioDefense, Inc. ("BioDefense") from CAC for a purchase price consisting of $200,000 in cash and 1,000,000 shares of the Issuer's common stock. After giving effect to the transactions under the SPA, the Issuer owns 80% (16,000,000) of the outstanding shares of BioDefense and CAC owns 20% (4,000,000) of the outstanding shares of BioDefense. Timothy Warbington is the Chairman and Chief Executive Officer of CAC, indirectly owns all of its outstanding shares of capital stock, and beneficially owns the shares held by CAC. Amount of shares of the Issuer's common stock beneficially owned following the reported transaction consists of 12,209 shares owned by Timothy Warbington, 1,000,000 shares owned by CAC, and 22,695 shares owned by Creative Medical Health, Inc. ("CMH"). Mr. Warbington is the President of CMH, owns substantially all of its outstanding shares of common stock and beneficially owns the shares held by CMH.
Recent transactions
Voluntary purchases and sales; administrative noise stays hidden.